OZ Biosciences是一家法国的新兴生物技术公司，其成立宗旨是帮助药物公司研发和生产新型的药物导入系统。研究方向主要集中在生物活性材料导入活体组织新技术的研发，2005年该技术研发获得了突破性进展，已经申请了多项国际专利。

OZ Biosciences公司的创办者是分子导入系统的国际权威，在此领域享有极高的声望。研发目标是建立新一代的核酸、蛋白、多肽和其它生物分子的转染导入系统，为广大科研工作者服务。该公司与许多国际知名企业、大学和科研机构有合作往来。OZ Biosciences公司产品极具特色，主打产品是基于纳米技术和生物技术的基础上发展起来的磁转染试剂，相对常规商业化转染试剂，其转染效率更高。

Since 2003, OZ Biosciences creates, develops and produces innovative   molecular delivery systems specialized in transfection and transduction   tools, for the worldwide scientific community and pharmaceutical   industry. OZ Biosciences is focused on delivery technologies of   biomolecules such as DNA, RNA and protein for in vitro and in vivo   applications.

These past years, the life sciences have gone through a technological   revolution. The progress achieved in genomic, functional genomic and   proteomic areas has created fabulous opportunities for better   understanding of basic biological processes and for the development   of the next generation of medicines.

OZ Biosciences公司主要产品线：

（1）Magnetofection™: a unique gene delivery method for in vitro and in vivo applications.

（2）Lipofection: proprietary biodegradable lipid-based transfection reagents.

（3）Transduction tools: for producing, concentrating, storing and enhancing virus efficiency.

（4）3D transfection: allowing nucleic acid delivery directly into 3D matrix.

（5）Protein delivery systems: including antibody & based on biodegradable lipid nanoparticles.

（6）Cell specific reagents: For specific cells such as neurons and stem cells.

（7）Vaccine Adjuvants: Standard & novel adjuvants for antigenic & genetic immunization

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

艾美捷科技代理3Helix品牌胶原蛋白杂交肽（CHP）。

胶原蛋白是几乎存在于所有人体组织中，在支持细胞生长和组织形成方面发挥着重要作用。胶原蛋白受损预示着结缔组织的损伤，也是多种涉及炎症和异常组织重塑的疾病的征兆，例如癌症、

心肌梗塞、关节炎、骨质疏松症和纤维化。然而，用传统技术很难定位受损的胶原蛋白。因此，3Helix公司开发了一系列专利性的胶原蛋白杂交肽，可直接定位受损的胶原蛋白分子。

3Helix产品包括：

（1）Auto-CHP：胶原蛋白杂交肽，用于自动染色的生物素结合物；

（2）B-CHP：胶原蛋白杂交肽，生物素结合物；

（3）F-CHP：胶原蛋白杂交肽，5-FAM 结合物；

（4）In vivo：胶原蛋白杂交肽，磺基-Cy7.5 结合物 (sCy7.5-CHP)；

（5）R-CHP：胶原蛋白杂交肽，Cy3 结合物。

Dendritics公司主要关注人类树突状细胞，希望找到能够促使CD34+造血前体细胞转化为树突状细胞（在GM-CSF和TNF-alpha存在的情况下）的细胞因子。在1992-2005年间，大量的研究使得研究者对人类树突状细胞的产生、细胞通路、C-type凝集素受体的功能及Toll-like受体的活性有了更深的理解。

DENDRITICS was started in 2005 by former members of SCHERING PLOUGH Laboratory for Immunological Research (LIR) in Dardilly, France. From their long experience at LIR, the team members of DENDRITICS have gathered complementary scientific and technological knowledge in different areas of immunology. The initial focus of LIR was in the biology of B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF) together with our colleagues of DNAX Research Institute in Palo Alto, California.

Our interest in cytokines led to the finding that human dendritic cells (DCs) could be generated in vitro from CD34+ hematopoietic progenitors cultured in the presence of GM-CSF and TNF-alpha.

The period from 1992 to 2005 saw the specialization of LIR in DC biology and was fuelled by a large-scale effort to discover and study the function of genes specifically expressed by these cells. This program led to a number of findings that contributed in particular to understanding the heterogeneity of DCs, the pathways regulating DC migration, the function of C-type lectin receptors in DCs and the activity of Toll-like receptors in DCs. Many novel genes were discovered through screening of cDNA libraries or through monoclonal antibodies raised against DCs.

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com